✦ LIBER ✦

Interferon-α plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients

✍ Scribed by A. Ferrajoli; A. M. Liberati; P. Caricchi; E. Donti; E. Morra; M. Lazzarino; A. R. Betti; P. Bernasconi; G. Saglio

Book ID: 114791931
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 450 KB
Volume: 55
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1995.tb00248.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of 11 patients with chronic my

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside

✍ J. Thaler; T. Fluckinger; H. Huber; A. Lang; C. Abbrederis; H. Seewann; H. Silly 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 459 KB

Combination therapy with interferon alph

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia

✍ Ursula B. Wandl; Otto Kloke; Marianne Nagel-Hiemke; Thomas Moritz; Reinhard Bech 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB

A randomized study comparing interferon

A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)

✍ T. Kühr; S. Burgstaller; U. Apfelbeck; W. Linkesch; H. Seewann; M. Fridrik; G. M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 269 KB

Randomized, parallel-group comparison of

Randomized, parallel-group comparison of interferon alfa-2b plus hydroxyurea versus hydroxyurea alone in patients with chronic myelogenous leukaemia in chronic phase

✍ Chong Won Park; Chi Hwa Han; Choon Choo Kim; Dong Jip Kim 📂 Article 📅 1991 🏛 Elsevier Science ⚖ 229 KB

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment

Long-term survival estimates for imatini

Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Kevin J. Anstrom; Shelby D. Reed; Andrew S. Allen; G. Alastair Glendenning; Kevi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views